---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103520"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:00:53.359639+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet

## Summary
- Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.
- Revenue $19.1M (vs $2.3M YoY) driven by $16.1M Menarini development milestone.
- R&D expenses $27.5M (vs $38.4M YoY) on lower clinical costs; SG&A $27.3M (vs $16.5M YoY) on pre-commercial investment.
- Net loss $17.4M compared to $39.0M in Q2 2024; improvement from higher revenue and lower R&D.
- EMA marketing authorisation application on track for 2H25; BROADWAY AD biomarker data showed significant p-tau217 reduction.

## SEC filing metadata
- accession: 0000950170-25-103520
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/0000950170-25-103520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/nams-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103520
- JSON: https://secwatch.observer/filing/0000950170-25-103520.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.